Israel Englander Annovis Bio, Inc. Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.61 - $13.87 $539,640 - $869,316	-62,676 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$11.84 - $19.78 $52,901 - $88,377	-4,468 Reduced 6.65%	62,676 $837,000
Q4 2021 Feb 14, 2022	BUY	$17.58 - $37.67 $26,809 - $57,446	1,525 Added 2.32%	67,144 $1.18 Million
Q3 2021 Nov 15, 2021	BUY	$30.95 - $120.97 $1.92 Million - $7.5 Million	62,032 Added 1729.36%	65,619 $2.08 Million
Q2 2021 Aug 16, 2021	BUY	$21.55 - $96.1 $77,299 - $344,710	3,587 New	3,587 $307,000
Q3 2020 Nov 16, 2020	SELL	$3.84 - $6.78 $146,607 - $258,853	-38,179 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.5 - $5.64 $95,447 - $215,329	38,179 New	38,179 $166,000

1.16M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $54.5M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.